

APPENDIX 3

Appendix 3: Supportive Care Utilization Patterns - Overall and by Treatment Cohort and Line of Therapy						
Characteristic	Overall Cohort	Additionally Treated[b]			Supportive Care Only[b]	
	Periods Of Gastric Cancer-related Supportive Care Utilization Assessment [c]					
	Overall Follow-up (N = 2583) n (%)	All Post-first-line Chemotherapy (N = 1415) n (%)	First-line Chemotherapy (N = 1415) n (%)	Second-line Chemotherapy (N = 1415) n (%)	All Post-first-line Chemotherapy (N = 1168) n (%)	First-line Chemotherapy (N=1168) n (%)
Post-index Prevalence of Supportive or Palliative Medications						
Palliative Surgery						
Had ≥1 claim, N (%)	41 (2)	31 (2)	3 (0)	25 (2)	6 (1)	2 (0)
<i>Number of claims</i>						
Mean	0.0	0.0	0.0	0.0	0.0	0.0
SD	0.2	0.2	0.0	0.2	0.1	0.0
Growth Factors						
Had ≥1 claim, N (%)	1704 (66)	903 (64)	735 (52)	790 (56)	397 (34)	567 (49)
<i>Number of claims</i>						
Mean	8.2	7.7	3.4	4.0	1.5	3.1
SD	14.8	14.4	6.4	8.8	6.2	6.5
Median	3	2	1	1	0	0
Granulocyte colony-stimulating factors						
Had ≥1 claim, N (%)	838 (32)	471 (33)	322 (23)	360 (25)	149 (13)	214 (18)
<i>Number of claims</i>						
Mean	2.7	2.7	1.3	1.4	0.3	1.0

Appendix 3: Supportive Care Utilization Patterns - Overall and by Treatment Cohort and Line of Therapy						
Characteristic	Overall Cohort	Additionally Treated[b]			Supportive Care Only[b]	
	Periods Of Gastric Cancer-related Supportive Care Utilization Assessment [c]					
	Overall Follow-up (N = 2583) n (%)	All Post-first-line Chemotherapy (N = 1415) n (%)	First-line Chemotherapy (N = 1415) n (%)	Second-line Chemotherapy (N = 1415) n (%)	All Post-first-line Chemotherapy (N = 1168) n (%)	First-line Chemotherapy (N=1168) n (%)
SD	8.5	8.8	4.1	6.4	1.0	4.0
Median	0	0	0	0	0	0
Erythropoietin-stimulating agents						
Had ≥1 claim, N (%)	1541 (60)	804 (57)	640 (45)	683 (48)	329 (28)	515 (44)
<i>Number of claims</i>						
Mean	5.9	5.4	2.3	2.8	1.3	2.3
SD	10.9	10.1	4.4	5.6	6.1	4.8
Median	1	1	0	0	0	0
Iron Therapy						
Had ≥1 claim, N (%)	164 (6)	58 (4)	49 (3)	37 (3)	18 (2)	61 (5)
<i>Number of claims</i>						
Mean	0.3	0.2	0.1	0.1	0.1	0.2
SD	2.1	1.5	1.1	1.1	1.9	1.2
Median	0	0	0	0	0	0
Antibiotics						
Had ≥1 claim, N (%)	736 (28)	310 (22)	220 (16)	190 (13)	132 (11)	190 (16)
<i>Number of claims</i>						
Mean	0.7	0.5	0.2	0.3	0.4	0.3
SD	2.3	1.6	0.7	1.1	2.4	1.0
Median	0	0	0	0	0	0
Antivirals						
Had ≥1 claim, N (%)	34 (1)	19 (1)	4 (0)	12 (1)	9 (1)	6 (1)

Appendix 3: Supportive Care Utilization Patterns - Overall and by Treatment Cohort and Line of Therapy						
Characteristic	Overall Cohort	Additionally Treated[b]			Supportive Care Only[b]	
	Periods Of Gastric Cancer-related Supportive Care Utilization Assessment [c]					
	Overall Follow-up (N = 2583) n (%)	All Post-first-line Chemotherapy (N = 1415) n (%)	First-line Chemotherapy (N = 1415) n (%)	Second-line Chemotherapy (N = 1415) n (%)	All Post-first-line Chemotherapy (N = 1168) n (%)	First-line Chemotherapy (N=1168) n (%)
<i>Number of claims</i>						
Mean	0.0	0.0	0.0	0.0	0.0	0.0
SD	0.3	0.2	0.1	0.2	0.1	0.2
Median	0	0	0	0	0	0
Antiemetics						
Had ≥1 claim, N (%)	2215 (86)	1043 (74)	1127 (80)	969 (68)	186 (16)	897 (77)
<i>Number of claims</i>						
Mean	8.6	6.7	5.0	3.6	0.3	4.6
SD	11.5	10.8	5.9	5.7	1.1	7.1
Median	5	3	3	2	0	2.5
Antifungals						
Had ≥1 claim, N (%)	62 (2)	30 (2)	16 (1)	16 (1)	13 (1)	10 (1)
<i>Number of claims</i>						
Mean	0.0	0.0	0.0	0.0	0.0	0.0
SD	0.3	0.2	0.1	0.2	0.1	0.2
Median	0	0	0	0	0	0
Pain Medications						
Had ≥1 claim, N (%)	1286 (50)	514 (36)	541 (38)	353 (25)	200 (17)	407 (35)
<i>Number of claims</i>						
Mean	1.7	1.4	0.7	0.7	0.5	0.7
SD	4.0	4.0	1.4	2.4	2.0	1.8
Median	0	0	0	0	0	0

Appendix 3: Supportive Care Utilization Patterns - Overall and by Treatment Cohort and Line of Therapy						
Characteristic	Overall Cohort	Additionally Treated[b]			Supportive Care Only[b]	
	Periods Of Gastric Cancer-related Supportive Care Utilization Assessment [c]					
	Overall Follow-up (N = 2583) n (%)	All Post-first-line Chemotherapy (N = 1415) n (%)	First-line Chemotherapy (N = 1415) n (%)	Second-line Chemotherapy (N = 1415) n (%)	All Post-first-line Chemotherapy (N = 1168) n (%)	First-line Chemotherapy (N=1168) n (%)
<i>Index Date Pre-2007, (N)</i>	(N=2214)	(N=1201)	(N=1201)	(N=1201)	(N=1013)	(N=1013)
Had ≥1 claim, N (%)	1007 (45)	399 (33)	413 (34)	275 (23)	144 (14)	310 (31)
<i>Number of claims</i>						
Mean	1.4	1.1	0.6	0.6	0.4	0.6
SD	3.3	3.4	1.1	2.3	1.9	1.7
Median	0	0	0	0	0	0
<i>Index Date 2007 or later, (N)</i>	(N=369)	(N=214)	(N=214)	(N=214)	(N=155)	(N=155)
Had ≥1 claim, N (%)	279 (76)	115 (54)	128 (60)	78 (36)	56 (36)	97 (63)
<i>Number of claims</i>						
Mean	3.7	2.9	1.5	1.3	1.1	1.5
SD	6.5	6.2	2.2	2.7	2.4	2.4
Median	2	1	1	0	0	1
Bisphosphonate						
Had ≥1 claim, N (%)	279 (76)	115 (54)	39 (3)	59 (4)	56 (36)	20 (2)
<i>Number of claims</i>						
Mean	0.3	0.4	0.1	0.2	0.1	0.1
SD	2.5	2.4	0.8	1.4	1.2	0.9
Median	0	0	0	0	0	0
Nutritional Support						
Had ≥1 claim, N (%)	139 (5)	90 (6)	205 (14)	206 (15)	22 (2)	192 (16)
<i>Number of claims</i>						
Mean	1.1	0.9	0.4	0.6	0.4	0.5

Appendix 3: Supportive Care Utilization Patterns - Overall and by Treatment Cohort and Line of Therapy						
Characteristic	Overall Cohort	Additionally Treated[b]			Supportive Care Only[b]	
	Periods Of Gastric Cancer-related Supportive Care Utilization Assessment [c]					
	Overall Follow-up (N = 2583) n (%)	All Post-first-line Chemotherapy (N = 1415) n (%)	First-line Chemotherapy (N = 1415) n (%)	Second-line Chemotherapy (N = 1415) n (%)	All Post-first-line Chemotherapy (N = 1168) n (%)	First-line Chemotherapy (N=1168) n (%)
SD	3.7	2.8	1.6	2.0	3.2	1.7
Median	0	0	0	0	0	0
PET						
Had ≥1 claim, N (%)	570 (22)	260 (18)	168 (12)	57 (4)	126 (11)	77 (7)
<i>Number of claims</i>						
Mean	0.2	0.1	0.1	0.1	0.0	0.1
SD	0.6	0.4	0.4	0.3	0.2	0.3
Median	0	0	0	0	0	0
Endoscopy						
Had ≥1 claim, N (%)	294 (11)	82 (6)	1344 (95)	555 (39)	19 (2)	1080 (92)
<i>Number of claims</i>						
Mean	2.8	1.4	1.8	0.9	0.6	1.7
SD	2.6	2.2	1.4	1.8	1.6	1.5
Median	2	1	1	0	0	1
CT						
Had ≥1 claim, N (%)	2491 (96)	774 (55)	1299 (92)	994 (70)	328 (28)	1063 (91)
<i>Number of claims</i>						
Mean	4.1	2.9	2.0	1.6	1.1	2.0
SD	3.3	2.9	1.7	1.9	1.8	1.7
Median	3	2	1	1	1	1
MRI						
Had ≥1 claim, N (%)	2487 (96)	1185 (84)	96 (7)	39 (3)	617 (53)	67 (6)

Appendix 3: Supportive Care Utilization Patterns - Overall and by Treatment Cohort and Line of Therapy						
Characteristic	Overall Cohort	Additionally Treated[b]			Supportive Care Only[b]	
	Periods Of Gastric Cancer-related Supportive Care Utilization Assessment [c]					
	Overall Follow-up (N = 2583) n (%)	All Post-first-line Chemotherapy (N = 1415) n (%)	First-line Chemotherapy (N = 1415) n (%)	Second-line Chemotherapy (N = 1415) n (%)	All Post-first-line Chemotherapy (N = 1168) n (%)	First-line Chemotherapy (N=1168) n (%)
<i>Number of claims</i>						
Mean	0.1	0.1	0.1	0.0	0.0	0.1
SD	0.6	0.4	0.4	0.2	0.3	0.3
Median	0	0	0	0	0	0
Radiography						
Had ≥1 claim, N (%)	237 (9)	65 (5)	495 (35)	390 (28)	33 (3)	509 (44)
<i>Number of claims</i>						
Mean	1.7	1.1	0.7	0.5	0.8	0.9
SD	2.4	1.8	1.4	1.1	1.6	1.5
Median	1	0	0	0	0	0
Blood Test						
Had ≥1 claim, N (%)	1591 (62)	645 (46)	1358 (96)	1275 (90)	416 (36)	1085 (93)
<i>Number of claims</i>						
Mean	20.8	17.5	9.3	9.6	4.7	9.0
SD	21.7	20.3	9.0	12.3	10.3	10.4
Median	14	12	7	6	2	6

SD = standard deviation; PET = positron emission tomography; CT = computed tomography; MRI = magnetic resonance imaging
Granulocyte-colony stimulating factors included filgrastim, pegfilgrastim, and sargramostim; erythropoietin-stimulating agents included erythropoietin and darbepoetin.
[a] Gastric cancer-related supportive care costs include palliative surgery, growth factors, iron supplements, antibiotics, antivirals, antiemetics, antifungals, pain medications, bisphosphonates, nutritional support, positron emission tomography, endoscopy, CT Scan, MRI, radiography, and blood tests.
[b] Patients receiving cancer-related treatments after the first-line chemotherapy completion date were categorized as “additionally

Appendix 3: Supportive Care Utilization Patterns - Overall and by Treatment Cohort and Line of Therapy						
	Overall Cohort	Additionally Treated[b]			Supportive Care Only[b]	
	Periods Of Gastric Cancer-related Supportive Care Utilization Assessment [c]					
	Overall Follow-up (N = 2583) n (%)	All Post-first-line Chemotherapy (N = 1415) n (%)	First-line Chemotherapy (N = 1415) n (%)	Second-line Chemotherapy (N = 1415) n (%)	All Post-first-line Chemotherapy (N = 1168) n (%)	First-line Chemotherapy (N=1168) n (%)
Characteristic						
treated,” and the remaining patients were categorized as "supportive care only."						
[c] Gastric cancer-related treatment and supportive care costs were assessed during the following pre-defined periods of assessment: (1) Overall follow-up period: the period between the index gastric cancer diagnosis date and death or the end of the database (December 31, 2009), whichever occurred first; (2) Post-first-line chemotherapy period: the period between the day immediately following the first-line chemotherapy administration end date and death or end of the database, whichever occurred first; (3) First-line chemotherapy period: the period between the gastric cancer index date and the first-line chemotherapy regimen end date; and (4) Second-line chemotherapy period: the period between the day immediately following the first-line chemotherapy regimen end date and the last date of the second-line chemotherapy regimen among patients who initiated second-line chemotherapy.						